相似文献
1
Adverse Events of DOACs in Children.
Front Pediatr. 2022 Jul 4;10:932085. doi: 10.3389/fped.2022.932085. eCollection 2022.
2
Venous thromboembolism and cancer: Current and future role of direct-acting oral anticoagulants.
Thromb Res. 2019 May;177:33-41. doi: 10.1016/j.thromres.2019.02.031. Epub 2019 Feb 27.
3
Which patients with unprovoked venous thromboembolism should receive extended anticoagulation with direct oral anticoagulants? A systematic review, network meta-analysis, and decision analysis.
J Eval Clin Pract. 2020 Feb;26(1):7-17. doi: 10.1111/jep.13194. Epub 2019 Jun 12.
4
Dabigatran Etexilate: A Review in Pediatric Venous Thromboembolism.
Paediatr Drugs. 2022 Jul;24(4):423-431. doi: 10.1007/s40272-022-00516-z. Epub 2022 Jun 14.
5
Treatment of Cancer-Associated Venous Thromboembolism with Low-Molecular-Weight Heparin or Direct Oral Anticoagulants: Patient Selection, Controversies, and Caveats.
Oncologist. 2021 Jan;26(1):e8-e16. doi: 10.1002/onco.13584. Epub 2020 Dec 4.
6
Differential benefit risk assessment of DOACs in the treatment of venous thromboembolism: focus on dabigatran.
Drug Des Devel Ther. 2015 Jul 9;9:3557-69. doi: 10.2147/DDDT.S70299. eCollection 2015.
7
Case-fatality of recurrent venous thromboembolism and major bleeding associated with aspirin, warfarin, and direct oral anticoagulants for secondary prevention.
Thromb Res. 2015 Feb;135(2):243-8. doi: 10.1016/j.thromres.2014.10.033. Epub 2014 Dec 2.
8
Direct oral anticoagulants for the treatment of cancer-associated venous thromboembolism. What do we know so far?
Hamostaseologie. 2017 Oct 27;37(4):241-255. doi: 10.5482/HAMO-16-09-0036. Epub 2017 May 16.
9
Direct oral anticoagulants for the treatment of cancer-associated venous thromboembolism.
Hamostaseologie. 2017;37(4):241-255. doi: 10.5482/HAMO-16-09-0036. Epub 2017 Dec 28.
10
Pharmacoeconomic evaluation of dabigatran, rivaroxaban and apixaban versus enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement in Spain.
Pharmacoeconomics. 2014 Sep;32(9):919-36. doi: 10.1007/s40273-014-0175-5.
引用本文的文献
1
Anticoagulant prescribing trends, bleeding events, and reversal agent use in pediatric patients: A retrospective, real-world study.
PLoS One. 2025 May 8;20(5):e0323137. doi: 10.1371/journal.pone.0323137. eCollection 2025.
2
Suspected adverse drug reactions of rivaroxaban reported in the United States food and drug administration adverse event reporting system database: a pharmacovigilance study.
Front Pharmacol. 2024 Sep 6;15:1399172. doi: 10.3389/fphar.2024.1399172. eCollection 2024.
3
How I treat pediatric venous thromboembolism in the DOAC era.
Blood. 2024 Feb 1;143(5):389-403. doi: 10.1182/blood.2022018966.
本文引用的文献
1
Thromboprophylaxis for Children Post-Fontan Procedure: Insights From the UNIVERSE Study.
J Am Heart Assoc. 2021 Nov 16;10(22):e021765. doi: 10.1161/JAHA.120.021765. Epub 2021 Sep 24.
2
Dabigatran etexilate for the treatment of acute venous thromboembolism in children (DIVERSITY): a randomised, controlled, open-label, phase 2b/3, non-inferiority trial.
Lancet Haematol. 2021 Jan;8(1):e22-e33. doi: 10.1016/S2352-3026(20)30368-9. Epub 2020 Dec 5.
3
Abnormal uterine bleeding in users of rivaroxaban and apixaban.
Hematology Am Soc Hematol Educ Program. 2020 Dec 4;2020(1):538-541. doi: 10.1182/hematology.2020000166.
4
Management of Venous Thromboembolism in Children: Current Recommendations and Therapeutic Options.
Ther Clin Risk Manag. 2020 Jul 28;16:673-679. doi: 10.2147/TCRM.S218622. eCollection 2020.
5
Safety of dabigatran etexilate for the secondary prevention of venous thromboembolism in children.
Blood. 2020 Feb 13;135(7):491-504. doi: 10.1182/blood.2019000998.
6
Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial.
Lancet Haematol. 2020 Jan;7(1):e18-e27. doi: 10.1016/S2352-3026(19)30219-4. Epub 2019 Nov 5.
7
Pathophysiology of thrombosis and anticoagulation post Fontan surgery.
Thromb Res. 2018 Dec;172:204-213. doi: 10.1016/j.thromres.2018.04.011. Epub 2018 Apr 14.
8
Extended use of dabigatran, warfarin, or placebo in venous thromboembolism.
N Engl J Med. 2013 Feb 21;368(8):709-18. doi: 10.1056/NEJMoa1113697.
9
Analysis of upper gastrointestinal adverse events among patients given dabigatran in the RE-LY trial.
Clin Gastroenterol Hepatol. 2013 Mar;11(3):246-52.e1-5. doi: 10.1016/j.cgh.2012.10.021. Epub 2012 Oct 24.
10
Oral rivaroxaban for symptomatic venous thromboembolism.
N Engl J Med. 2010 Dec 23;363(26):2499-510. doi: 10.1056/NEJMoa1007903. Epub 2010 Dec 3.
Zotero 插件